Clinical trials: Allergy and Asthma
Asthma, Cockroach Hypersensitivity
Cockroach Nasal Allergen Challenge Pilot
This research is being done to look at the body's response to cockroach extract, an allergen, when sprayed into the nose. The spraying of the cockroach extract into the participant's nose is called Nasal Allergen Challenge (NAC).
- Trial name
- NCT02710136
- Testing
- Glycerinated German Cockroach Allergenic Extract
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma, Aspirin-induced
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
To diagnose aspirin hypersensitivity in asthmatics by using and safe, low-dose aspirin oral challenge. Hypothesis 1: A low dose of oral ASA (20 or 40 mg) will induce significantly different concentrations of arachidonic acid…
- Trial name
- ASAS (NCT01320072)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Montefiore Medical Center
Asthma
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller…
- Trial name
- PONENTE (NCT03557307)
- Testing
- Benralizumab
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Asthma
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent…
- Trial name
- NCT03226392
- Testing
- QAW039
- Where
- 142 sites in United States, Brazil and 16 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of MAP0010 in Asthmatic Children and Adolescents
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
- Trial name
- NCT00697801
- Testing
- MAP0010 low dose, MAP0010 high dose
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Allergan
Asthma
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma
The purpose of this study is to test if Symbicort (budesonide/formoterol) Turbuhaler is effective in treating asthma when used 'as needed' in patients with milder asthma.
- Trial name
- SYGMA2 (NCT02224157)
- Testing
- budesonode bid + terbutaline 'as needed'
- Where
- 340 sites in Australia, Brazil and 23 more
- Volunteers
- 4,215 people
- Sponsor
- AstraZeneca
Medication Adherence, Medication Compliance
Connected Healthcare for Individuals Living at Home With Chronic Conditions
Managing and taking medications as prescribed can be a difficult task. This is especially true for older adults living at home with chronic conditions while managing multiple prescribed medications.
- Conditions
- Medication Adherence, Medication Compliance, Medication Nonadherence, Hypertension
- Trial name
- NCT04339296
- Testing
- Spencer
- Where
- Canada
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Alberta Health Services, Calgary
Asthma
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Trial name
- NCT05363670
- Testing
- ARS-1 1 mg, Albuterol MDI, ARS-1 2mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge.
- Trial name
- ACE (NCT02230189)
- Testing
- Segmental airway allergen challenge, Bronchoscopy, Methacholine challenge test
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Prescott Woodruff
Asthma, Healthy Participants
A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive
The primary objective of the study is to characterize the PK of single doses of salbutamol in healthy participants delivered via an MDI containing propellant HFA-152a (test), and to compare with an MDI containing propellant…
- Trial name
- NCT06433908
- Testing
- Salbutamol HFA-152a, Salbutamol HFA-134a
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges
- Trial name
- NCT05555290
- Testing
- PT027, PT007
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Asthma
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma
- Trial name
- NAVIGATOR (NCT03347279)
- Testing
- Experimental: Tezepelumab
- Where
- 289 sites in United States, Argentina and 16 more
- Volunteers
- 1,061 people
- Sponsor
- AstraZeneca
Asthma
Symptom Perception
Older asthmatics have considerably worse outcomes than younger patients with asthma. In this study, the investigators will evaluate the role of symptom perception as a key determinant of poorer outcomes and lower adherence to…
- Trial name
- NCT03646669
- Testing
- PEF Feedback, Asthma education
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease
Social Work Intervention Focused on Transitions
In response to Program Announcement (PA)-09-164, "NIH Exploratory/Developmental Research Grant Program (R21) a randomized pilot study testing the efficacy of SWIFT: Social Work Intervention Focused on Transitions among at-risk…
- Conditions
- Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension
- Trial name
- SWIFT (NCT02232126)
- Testing
- SWIFT home intervention
- Where
- 2 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Asthma
Effect of Symbicort on GR Localisation in Asthma
To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg)…
- Trial name
- NCT00159263
- Testing
- Formoterol Inhalant Powder, Budesonide Powder, Budesonide and Formoterol Product
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Imperial College London
Asthma
Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma
This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary PD of cumulative doses of AS MDI compared to cumulative doses of Proventil as an…
- Trial name
- NCT03371459
- Testing
- AS MDI, Proventil
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Asthma
Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma
Brief Summary: The purpose of this study is to characterize the dose response of GSK573719 in combination with Fluticasone furoate 100mcg in patients with asthma.
- Trial name
- ILA115938 (NCT01573624)
- Testing
- FF/GSK573719, FF, FF/VI
- Where
- 32 sites in United States, Argentina and 3 more
- Volunteers
- 421 people
- Sponsor
- GlaxoSmithKline
Asthma
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
- Trial name
- MUPPITS-2 (NCT03292588)
- Testing
- Mepolizumab
- Where
- 9 sites in United States
- Volunteers
- 335 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim